Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navitoclax, Venetoclax, and Decitabine in R/R AML
NCT05222984Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Sep 2022
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of navitoclax in acute myeloid leukemia (AML), sponsored by City of Hope. Primary endpoint: Incidence of adverse events up to 1 year. Started Sep 2022; status: active, not recruiting.
02
Drugs
navitoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05222984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05222984.